about
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaThe incidence of renal cancer in Polish National Cancer Registry: is there any epidemiological data we can rely on?Urinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches.Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinomaUsage of invisible near infrared light (NIR) fluorescence with indocyanine green (ICG) and methylene blue (MB) in urological oncology. Part 1.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal cell carcinoma: how to hit the targets?
@en
Renal cell carcinoma: how to hit the targets?
@nl
type
label
Renal cell carcinoma: how to hit the targets?
@en
Renal cell carcinoma: how to hit the targets?
@nl
prefLabel
Renal cell carcinoma: how to hit the targets?
@en
Renal cell carcinoma: how to hit the targets?
@nl
P2093
P2860
P1476
Renal cell carcinoma: how to hit the targets?
@en
P2093
Alexander Shulyak
Marjan Tarchynets
Oleg Banyra
P2860
P304
P356
10.5173/CEJU.2013.04.ART2
P577
2014-01-27T00:00:00Z